CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,220,350 | -22.2% | 193,328 | +13.3% | 0.00% | 0.0% |
| Q2 2023 | $5,422,707 | +91.0% | 170,579 | +46.5% | 0.00% | – |
| Q1 2023 | $2,839,801 | +32.6% | 116,433 | +71.5% | 0.00% | – |
| Q4 2022 | $2,141,566 | -47.0% | 67,900 | -52.6% | 0.00% | – |
| Q3 2022 | $4,044,000 | -70.4% | 143,121 | -72.3% | 0.00% | -100.0% |
| Q2 2022 | $13,675,000 | +513.2% | 517,234 | +712.1% | 0.00% | – |
| Q1 2022 | $2,230,000 | -83.7% | 63,691 | -84.9% | 0.00% | -100.0% |
| Q4 2021 | $13,705,000 | -31.8% | 422,744 | -37.9% | 0.00% | -60.0% |
| Q3 2021 | $20,088,000 | -21.3% | 680,915 | -31.7% | 0.01% | 0.0% |
| Q2 2021 | $25,526,000 | +51.6% | 996,365 | -18.8% | 0.01% | +25.0% |
| Q1 2021 | $16,843,000 | -26.5% | 1,226,729 | -11.2% | 0.00% | -33.3% |
| Q4 2020 | $22,906,000 | – | 1,381,556 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |